{"id":297,"date":"2023-10-11T15:06:29","date_gmt":"2023-10-11T13:06:29","guid":{"rendered":"https:\/\/zutat.gmbh\/faq\/"},"modified":"2024-04-09T16:23:28","modified_gmt":"2024-04-09T14:23:28","slug":"faq","status":"publish","type":"page","link":"https:\/\/zutat.gmbh\/en\/faq\/","title":{"rendered":"FAQ"},"content":{"rendered":"\n\n<section id=\"block-faq-block_ad788343d406e3c4983e6700b92b0b45\" class=\"block block-faq pt-large pb-medium\">\n    <div class=\"container\">\n            <h1 class=\"screen-reader-text\">FAQ<\/h1>\n                <h2 class=\"display2\">Questions about my services<\/h2>\n        <div class=\"faqs content\">\n            <div class=\"faq\">\n            <h3 class=\"question display6\">Which areas does Zutat specialise in?<\/h3>\n            <div class=\"answer\"><p>Zutat is specialised in reimbursement for the following in the Swiss healthcare market:<\/p>\n<ul>\n<li>Medical devices<\/li>\n<li>Foods for Special Medical Purposes (FSMP)<\/li>\n<li>Services associated with these products<\/li>\n<\/ul>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">What are the central services offered by Zutat?<\/h3>\n            <div class=\"answer\"><ul>\n<li>Providing support with the development of a market access strategy<\/li>\n<li>Clarifying whether a product is reimbursed or whether reimbursement is possible<\/li>\n<li>Outlining the treatment pathway and calculating the cost implications<\/li>\n<li>Tracking down market statistics<\/li>\n<li>Guiding and supporting customers as they take steps towards obtaining reimbursement for medical devices<\/li>\n<li>Reimbursement for services in connection with the supply of medical devices<\/li>\n<\/ul>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Does Zutat also assist pharmaceutical companies?<\/h3>\n            <div class=\"answer\"><p>Yes. We also assist pharmaceutical companies with queries related to medical devices. However, we cannot provide assistance in the area of medicines. \u2018Pharma\u2019 is another world, which we are not so well acquainted with.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Is Zutat also an importer\/distributor of medical devices?<\/h3>\n            <div class=\"answer\"><p>No. Zutat can aid in the search, but it does not play the role of a trading partner.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Can Zutat provide brief, succinct answers to questions about market access and reimbursement?<\/h3>\n            <div class=\"answer\"><p>Yes. We offer a readily available service to eliminate the need for time-consuming searching. We can also answer close-ended questions. Simply book a time slot and we\u2019ll provide answers. The service will be billed at the time of booking.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Is Zutat familiar with the MiGeL list of medical supplies and devices?<\/h3>\n            <div class=\"answer\"><p>Yes. To some Rolf M\u00fcller is known as Mr MiGeL. He is very familiar with MiGeL practices and the structure and peculiarities of MiGeL.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Does Zutat also offer services outside Switzerland?<\/h3>\n            <div class=\"answer\"><p>No. Zutat\u2019s services are only available in Switzerland. When it comes to other countries, we do not possess the level of knowledge\/insight required to provide the quality that we strive for.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">What market statistics\/facts can Zutat offer?<\/h3>\n            <div class=\"answer\"><p>Zutat can provide publicly available statistics and a literature search.<\/p>\n<p>Potential sources include:<\/p>\n<ul>\n<li>The Federal Statistical Office<\/li>\n<li>The National Agency for Cancer Registration<\/li>\n<li>Healthcare provider associations<\/li>\n<\/ul>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Who determines product prices in Switzerland?<\/h3>\n            <div class=\"answer\"><p>Free competition exists in the medical device sector. Economic actors set the price of each product. There are no margin constraints.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Is it possible to be reimbursed for my medical device?<\/h3>\n            <div class=\"answer\"><p>Is the product marketable in Switzerland?<\/p>\n<p><strong>No:<\/strong> reimbursement will not be provided<\/p>\n<p><strong>Yes:<\/strong><\/p>\n<ul>\n<li><strong>Use by healthcare providers (without care)<br \/>\n<\/strong>The product is an essential part of the service. Reimbursement is stipulated in the tariff contracts of the healthcare providers.<br \/>\n<strong>Inpatient hospital services:<\/strong> medical devices are part of the flat rate and are not charged separately (SwissDRG)<br \/>\n<strong>Outpatient services offered by a hospital or doctor\u2019s surgery:<\/strong> TARMED tariff system for outpatient medical services, General Interpretation on the Reimbursement of Consumables and Implants (GI-20).<br \/>\nCost bearer: <a href=\"https:\/\/browser.tartools.ch\/#\/tarmed_uvg\/data\/I\/20\" target=\"_blank\" rel=\"noopener\">accident or disability insurance<\/a><br \/>\nCost bearer: <a href=\"https:\/\/browser.tartools.ch\/#\/tarmed_kvg\/data\/I\/20\" target=\"_blank\" rel=\"noopener\">health insurance<\/a><br \/>\nException: if the service is <strong>not<\/strong> subject to reimbursement, the consumables cannot be reimbursed either (an essential part of the service).<br \/>\n<a href=\"https:\/\/www.physioswiss.ch\/de\" target=\"_blank\" rel=\"noopener\">Tariff contract for physiotherapy<\/a><br \/>\n<a href=\"https:\/\/www.ergotherapie.ch\/berufsausuebung\/tarifvertraege\/\" target=\"_blank\" rel=\"noopener\">Tariff contract for occupational therapy<\/a><br \/>\n<a href=\"https:\/\/www.swiss-medtech.ch\/en\/section\/rehabilitation\/tariff-documents\" target=\"_blank\" rel=\"noopener\">Tariff for wheelchair provision<\/a><br \/>\nMore tariffs\/tariff structures are available on request.<\/li>\n<li><strong>Use as part of a care service (medical care product)<br \/>\n<\/strong>Medically prescribed services are provided by an outpatient or inpatient care organisation or self-employed nurses. Does the required medical care product correspond to a generic <a href=\"http:\/\/www.bag.admin.ch\/migel\" target=\"_blank\" rel=\"noopener\">MiGeL<\/a> item (please note the prohibition of analogy)?<\/p>\n<ul>\n<li><strong>No:<\/strong> no reimbursement e.g. separate reimbursement is provided. The application process is the sole process designed for listing. The <a href=\"https:\/\/www.bag.admin.ch\/bag\/de\/home\/versicherungen\/krankenversicherung\/krankenversicherung-bezeichnung-der-leistungen\/antragsprozesse\/Antragsprozesse-Mittel-undGegenstaendeliste.html\" target=\"_blank\" rel=\"noopener\">application process<\/a> must be completed for an amendment to be made to the MiGeL.<\/li>\n<li><strong>Yes:<\/strong> separate reimbursement is possible (with the exception of simple consumables related to the care service and multiple-use products for different persons)<\/li>\n<\/ul>\n<\/li>\n<li><strong>Self-use by the insured person<\/strong><br \/>\nIs the medical device used by the patient themselves, if necessary with the assistance of non-professional parties?<\/p>\n<ul>\n<li><strong>No:<\/strong> see \u2018Use by healthcare provider\u2019 and \u2018Use as part of a care service\u2019 above.<\/li>\n<li><strong>Ja:<\/strong> if the medical device corresponds to a generic <a href=\"http:\/\/www.bag.admin.ch\/migel\" target=\"_blank\" rel=\"noopener\">MiGeL<\/a> item (please note the prohibition of analogy)?<\/li>\n<li><strong>If a corresponding MiGeL item is missing:<\/strong> amendments to the MiGeL are possible. To this end, the application process must be completed.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>\n        <\/div>\n            <\/div>\n<\/section>\n\n\n\n\n<section id=\"block-banner-block_90a9e3daaad5dc4055484f020a44bf43\" class=\"block block-banner \">\n    <div class=\"image\">\n        <img decoding=\"async\" width=\"1440\" height=\"533\" data-src=\"https:\/\/zutat.gmbh\/wp-content\/uploads\/2023\/10\/RolfMitLaptopAufDerSchoss-1440x533.jpeg\" class=\"attachment-banner size-banner lazyload\" alt=\"\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1440px; --smush-placeholder-aspect-ratio: 1440\/533;\" \/>    <\/div>\n<\/section>\n\n\n\n\n<section id=\"block-faq-block_d2f7a5855fec7387ab5d1e9347bbaa97\" class=\"block block-faq pt-large pb-medium\">\n    <div class=\"container\">\n                <h2 class=\"display2\">Questions about the list of medical supplies and devices (MiGeL)<\/h2>\n        <div class=\"faqs content\">\n            <div class=\"faq\">\n            <h3 class=\"question display6\">Is MiGeL binding?<\/h3>\n            <div class=\"answer\"><p>Yes, in the area of compulsory health insurance. The MiGeL is an exhaustive approved list that is part of the FDHA (Federal Department of Home Affairs) Ordinance on Compulsory Health Insurance Benefits (HIBO).<\/p>\n<p>Link MiGeL:\u00a0<strong><a href=\"https:\/\/www.bag.admin.ch\/bag\/de\/home\/versicherungen\/krankenversicherung\/krankenversicherung-leistungen-tarife\/Mittel-und-Gegenstaendeliste.html\" target=\"_blank\" rel=\"noopener\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.bag.admin.ch\/bag\/de\/home\/versicherungen\/krankenversicherung\/krankenversicherung-leistungen-tarife\/Mittel-und-Gegenstaendeliste.html&amp;source=gmail&amp;ust=1711709190909000&amp;usg=AOvVaw0A1i9DFk80GgmWi2c7CjIG\">list of medical supplies and devices (MiGeL) (admin.ch)<\/a><\/strong><\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Does the Maximum Reimbursement Amount (HVB) correspond to a product price?<\/h3>\n            <div class=\"answer\"><p>No. The HVB is the maximum amount that compulsory health insurance may reimburse. If a product is cheaper, the insurance company pays the actual costs. If a product is more expensive, the insured person pays the additional costs.<\/p>\n<p>The HVB is the median of the products available on the market, taking into account foreign prices.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">How can I change the MiGeL if I do not agree with the content or items are missing?<\/h3>\n            <div class=\"answer\"><p>Amendments can only be obtained by submitting an application. All persons and organisations wishing to amend the MiGeL can submit an application.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Foods for Special Medical Purposes (FSMP) are also included in the MiGeL. Does Zutat also offer help in this area?<\/h3>\n            <div class=\"answer\"><p>Yes. Services such as clarifying the feasibility of reimbursement and assisting in the process of obtaining it are also offered for FSMP products.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Who takes the decision regarding the MiGeL amendment application?<\/h3>\n            <div class=\"answer\"><p>The Federal Department of Home Affairs issues the MiGeL after consulting the Federal Commission for Analyses, Aids and Devices.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Where can I access information about changes to the MiGeL?<\/h3>\n            <div class=\"answer\"><p>The Federal Office of Public Health issues a <strong><a href=\"https:\/\/www.nlt.admin.ch\/f\/s.aspx?1A885DAEF2EA974EBDA31AC8BE46475BB0\" target=\"_blank\" rel=\"noopener\">newsletter<\/a><\/strong>. It is highly recommended to sign up for this as soon as possible so that you receive timely updates regarding any changes.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Are there any transitional periods in place before amendments to the MiGeL come into force?<\/h3>\n            <div class=\"answer\"><p>The \u2018valid from\u2019 date shown for each MiGeL item is binding, and there is no entitlement to a further transitional period.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Who assigns the correct MiGeL item to medical devices?<\/h3>\n            <div class=\"answer\"><p>It is the invoicing party\u2019s responsibility to apply the correct MiGeL item.<\/p>\n<\/div>\n        <\/div>\n                <div class=\"faq\">\n            <h3 class=\"question display6\">Can the insurance company refuse to provide reimbursement even if a product can be assigned to a MiGeL item?<\/h3>\n            <div class=\"answer\"><p>Yes. If:<\/p>\n<ul>\n<li>the product is not marketable in Switzerland;<\/li>\n<li>there is no doctor\u2019s order\/prescription;<\/li>\n<li>the product\u2019s use does not meet the WZW criteria (with regard to efficacy, appropriateness and cost-effectiveness);<\/li>\n<li>the product does not correspond to a MiGeL item;<\/li>\n<li>a limitation rules out reimbursement; and\/or<\/li>\n<li>dispensation took place via an unauthorised channel.<\/li>\n<\/ul>\n<\/div>\n        <\/div>\n            <\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-297","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/zutat.gmbh\/en\/wp-json\/wp\/v2\/pages\/297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zutat.gmbh\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/zutat.gmbh\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/zutat.gmbh\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/zutat.gmbh\/en\/wp-json\/wp\/v2\/comments?post=297"}],"version-history":[{"count":0,"href":"https:\/\/zutat.gmbh\/en\/wp-json\/wp\/v2\/pages\/297\/revisions"}],"wp:attachment":[{"href":"https:\/\/zutat.gmbh\/en\/wp-json\/wp\/v2\/media?parent=297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}